Camarda, Floriana
 Distribuzione geografica
Continente #
NA - Nord America 163
EU - Europa 148
AS - Asia 45
AF - Africa 2
Totale 358
Nazione #
US - Stati Uniti d'America 161
IT - Italia 65
SE - Svezia 21
CN - Cina 18
IE - Irlanda 18
SG - Singapore 16
AT - Austria 12
FR - Francia 8
DE - Germania 6
GB - Regno Unito 4
IN - India 4
KR - Corea 4
NL - Olanda 4
FI - Finlandia 3
RU - Federazione Russa 3
CA - Canada 2
CH - Svizzera 2
CI - Costa d'Avorio 2
TH - Thailandia 2
BE - Belgio 1
GR - Grecia 1
TR - Turchia 1
Totale 358
Città #
Ashburn 36
Chandler 27
Rome 22
Dublin 18
New York 12
Vienna 12
Milan 11
Chicago 8
Singapore 8
Beijing 7
Washington 6
Amsterdam 4
Bari 4
New Haven 4
Asti 3
Busto Arsizio 3
Jeju City 3
Moscow 3
Paris 3
Princeton 3
Wilmington 3
Abidjan 2
Bangkok 2
Boston 2
Guidonia Montecelio 2
Helsinki 2
Legnano 2
London 2
Marseille 2
Menlo Park 2
Mumbai 2
Nave 2
Osimo 2
Piacenza 2
Toronto 2
Ann Arbor 1
Boydton 1
Bremen 1
Cambridge 1
Dortmund 1
Fairfield 1
Houston 1
Lappeenranta 1
Mechelen 1
Molfetta 1
Phoenixville 1
Piraeus 1
Pune 1
Saint-maur-des-fossés 1
San Diego 1
San Mateo 1
Seattle 1
Suyeong-gu 1
Tappahannock 1
Woodbridge 1
Totale 248
Nome #
Management of single pulmonary metastases from colorectal cancer: State of the art 66
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation 60
Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report 53
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 33
PARP Inhibitors Resistance: Mechanisms and Perspectives 25
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 23
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 22
Recent progress in the use of pharmacotherapy for endometrial cancer 22
Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids 20
Advanced and recurrent endometrial cancer: State of the art and future perspectives 17
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives 16
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 13
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 5
Totale 375
Categoria #
all - tutte 2.580
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.580


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20219 0 0 0 0 0 0 0 0 8 0 1 0
2021/202237 1 0 0 3 1 0 1 2 0 5 16 8
2022/2023132 15 11 7 15 7 11 10 6 10 12 19 9
2023/2024190 3 30 18 22 9 26 27 4 4 8 20 19
2024/20257 7 0 0 0 0 0 0 0 0 0 0 0
Totale 375